Metformin and cancer: licence to heal?

Bibliography

• Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 2005;92:2076-83
   PubMed Web of Science ®Google Scholar
• Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer 2007;121:856-62
   PubMed Web of Science ®Google Scholar
• Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst 2005;97:1679-87
   PubMed Web of Science ®Google Scholar
• Friberg E, Orsini N, Mantzoros CS, Wolk A. Diabetes mellitus and risk of endometrial cancer: a meta-analysis. Diabetologia 2007;50:1365-74
   PubMed Web of Science ®Google Scholar
• Larsson SC, Orsini N, Brismar K, Wolk A. Diabetes mellitus and risk of bladder cancer: a meta-analysis. Diabetologia 2006;49:2819-23
   PubMed Web of Science ®Google Scholar
• Papanas N, Giatromanolaki A, Galazios G, Endometrial carcinoma and diabetes revisited. Eur J Gynaecol Oncol 2006;27:505-8
   PubMed Web of Science ®Google Scholar
• Renehan AG, Frystyk J, Flyvbjerg A. Obesity and cancer risk: the role of the insulin-IGF axis. Trends Endocrinol Metab 2006;17:328-36
   PubMed Web of Science ®Google Scholar
• Pischon T, Nothlings U, Boeing H. Obesity and cancer. Proc Nutr Soc 2008;67:128-45
   PubMed Web of Science ®Google Scholar
• Lang K, Ratke J. Leptin and adiponectin: new players in the field of tumor cell and leukocyte migration. Cell Commun Signal 2009;7:27
   PubMed Web of Science ®Google Scholar
• Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006;29:254-8
   PubMed Web of Science ®Google Scholar
• Monami M, Lamanna C, Balzi D, Sulphonylureas and cancer: a case-control study. Acta Diabetol 2009;46:279-84
   PubMed Web of Science ®Google Scholar
• Yang YX, Hennessy S, Lewis JD. Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology 2004;127:1044-50
   PubMed Web of Science ®Google Scholar
• Hemkens LG, Grouven U, Bender R, Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 2009;52:1732-44
   PubMed Web of Science ®Google Scholar
• Smith U, Gale EAM. Does diabetes therapy influence the risk of cancer? Diabetologia 2009;52:1699-708
   PubMed Web of Science ®Google Scholar
• Ebeling P, Tuominen JA, Koivisto VA. Insulin analogues and carcinoma of the breast. Diabetologia 1996;39:124-5
   PubMed Web of Science ®Google Scholar
• Draznin B. Mitogenic action of insulin: friend, foe or ‘frenemy’? Diabetologia 2010;53:229-33
   PubMed Web of Science ®Google Scholar
• Ramos-Nino ME, MacLean CD, Littenberg B. Association between cancer prevalence and use of thiazolidinediones: results from the Vermont Diabetes Information System. BMC Med 2007;5:17
   PubMed Web of Science ®Google Scholar
• Evans JM, Donnelly LA, Emslie-Smith AM, Metformin and reduced risk of cancer in diabetic patients. BMJ 2005;330:1304-5
   PubMed Web of Science ®Google Scholar
• Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009;52:1766-77
   PubMed Web of Science ®Google Scholar
• Wright JL, Stanford JL. Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. Cancer Causes Control 2009;20:1617-22
   PubMed Web of Science ®Google Scholar
• Bodmer M, Meier C, Krahenbuhl S, Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care 2010;33:1304-8
   PubMed Web of Science ®Google Scholar
• Zakikhani M, Dowling R, Fantus IG, Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 2006;66:10269-73
   PubMed Web of Science ®Google Scholar
• Dowling RJ, Zakikhani M, Fantus IG, Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 2007;67:10804-12
   PubMed Web of Science ®Google Scholar
• Ben Sahra I, Laurent K, Loubat A, The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 2008;27:3576-86
   PubMed Web of Science ®Google Scholar
• Buzzai M, Jones RG, Amaravadi RK, Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 2007;67:6745-52
   PubMed Web of Science ®Google Scholar
• Huang X, Wullschleger S, Shpiro N, Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. Biochem J 2008;412:211-21
   PubMed Web of Science ®Google Scholar
• Anisimov VN, Berstein LM, Egormin PA, Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Exp Gerontol 2005;40:685-93
   PubMed Web of Science ®Google Scholar
• Jiralerspong S, Palla SL, Giordano SH, Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 2009;27:3297-302
   PubMed Web of Science ®Google Scholar
• Li D, Yeung SC, Hassan MM, Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 2009;137:482-8
   PubMed Web of Science ®Google Scholar
• Bailey CJ, Turner RC. Metformin. New Engl J Med 1996;334:574-9
   PubMed Web of Science ®Google Scholar
• Yang YX. Do diabetes drugs modify the risk of pancreatic cancer? Gastroenterology 2009;137:412-15
   PubMed Web of Science ®Google Scholar
• Goodwin PJ, Ligibel JA, Stambolic V. Metformin in breast cancer: time for action. J Clin Oncol 2009;27:3271-3
   PubMed Web of Science ®Google Scholar
• Zhou G, Myers R, Li Y, Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001;108:1167-74
   PubMed Web of Science ®Google Scholar
• Zakikhani M, Dowling RJ, Sonenberg N, Pollak MN. The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Prev Res (Phila Pa) 2008;1:369-75
   PubMed Web of Science ®Google Scholar
• Jones RG, Plas DR, Kubek S, AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell 2005;18:283-93
   PubMed Web of Science ®Google Scholar
• Liang J, Shao SH, Xu ZX, The energy sensing LKB1-AMPK pathway regulates p27 (kip1) phosphorylation mediating the decision to enter autophagy or apoptosis. Nat Cell Biol 2007;9:218-24
   PubMed Web of Science ®Google Scholar
• Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell 2003;115:577-90
   PubMed Web of Science ®Google Scholar
• Vazquez-Martin A, Oliveras-Ferraros C, Del Barco S, If mammalian target of metformin indirectly is mammalian target of rapamycin, then the insulin-like growth factor-1 receptor axis will audit the efficacy of metformin in cancer clinical trials. J Clin Oncol 2009;27:e207-9
   PubMed Web of Science ®Google Scholar
• Grenader T, Goldberg A, Shavit L. Metformin as an addition to conventional chemotherapy in breast cancer. J Clin Oncol 2009;27:e259
   PubMed Web of Science ®Google Scholar
• Pearce EL, Walsh MC, Cejas PJ, Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature 2009;460:103-7
   PubMed Web of Science ®Google Scholar
• Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res 2009;69:7507-11
   PubMed Web of Science ®Google Scholar
• Xavier DO, Amaral LS, Gomes MA, Metformin inhibits inflammatory angiogenesis in a murine sponge model. Biomed Pharmacother 2010;64:220-5
   PubMed Web of Science ®Google Scholar
• Wysocki PJ, Wierusz-Wysocka B. Obesity, hyperinsulinemia and breast cancer: novel targets and a novel role for metformin. Expert Rev Mol Diagn 2010;10:509-19
   PubMed Web of Science ®Google Scholar
• Phoenix KN, Vumbaca F, Claffey KP. Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model. Breast Cancer Res Treat 2009;113:101-11
   PubMed Web of Science ®Google Scholar
• Papanas N, Maltezos E, Mikhailidis DP. Metformin: diamonds are forever. Expert Opin Pharmacother 2009;10:2395-7
   PubMed Web of Science ®Google Scholar